At the 2026 JPM Conference in San Francisco, Astellas President and CEO Naoki Okamura spoke with STAT Brand Studio Editor Jesse McQuarters about the company’s strategy and long-term vision as it enters an important phase in the company’s evolution. Astellas is taking a patient-centered approach and investing in four key areas within R&D — targeted protein degradation, immuno-oncology, blindness and regeneration, and genetic regulation — as it prepares for the loss of exclusivity of its leading prostate cancer therapy.

Read more here: https://www.statnews.com/sponsor/2026/02/23/astellas-ceo-talks-transformative-medicines-driving-growth/